8-K Announcements
6Material company update
Feb 6, 2026·SEC
Material company update
Dec 12, 2025·SEC
Material company update
Dec 11, 2025·SEC
Immunovant, Inc.(IMVT)Earnings, Financials & Key Ratios
IMVT•NASDAQ
$28.67
$5.83B mkt cap·Price updated May 6, 2026
AboutImmunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.Show more
- Revenue$0
- EBITDA-$438M-62.2%
- Net Income-$414M-59.6%
- EPS (Diluted)-2.73-45.2%
- ROE-62.46%-18.0%
- Debt/Equity0.00-37.7%
IMVT Key Insights
Immunovant, Inc. (IMVT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 80 (top 20%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IMVT Price & Volume
Immunovant, Inc. (IMVT) stock price & volume — 10-year historical chart
Loading chart...
IMVT Growth Metrics
Immunovant, Inc. (IMVT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2.67%
Return on Capital
10 Years-54.33%
5 Years-50.32%
3 Years-57.06%
Last Year-66.11%
IMVT Recent Earnings
Immunovant, Inc. (IMVT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q1 2026Latest
Feb 6, 2026EPS
$0.61
Est $0.72
+15.3%
Revenue
—
Est $6M
Q4 2025
Nov 10, 2025EPS
$0.73
Est $0.72
-1.4%
Revenue
—
Q3 2025
Aug 11, 2025EPS
$0.60
Est $0.69
+13.0%
Revenue
—
Q2 2025
May 29, 2025EPS
$0.64
Est $0.71
+10.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 6, 2026 | $0.61vs $0.72+15.3% | —vs $6M |
| Q4 2025 | Nov 10, 2025 | $0.73vs $0.72-1.4% | — |
| Q3 2025 | Aug 11, 2025 | $0.60vs $0.69+13.0% | — |
| Q2 2025 | May 29, 2025 | $0.64vs $0.71+10.3% | — |
Based on last 12 quarters of dataView full earnings history →
IMVT Peer Comparison
Immunovant, Inc. (IMVT) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 VKTX | 3.74B | 32.28 | -10.12 | -71.31% | 0.00 | |||
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 DAWN | 2.22B | 21.53 | -20.70 | 20.6% | -67.85% | -23.43% | 0.01 | |
 ALXO | 111.98M | 2.09 | -0.81 | -241.09% | 0.15 | |||
 HALO | 7.81B | 66.35 | 25.92 | 37.55% | 22.69% | 6.49% | ||
 UTHR | 26.13B | 596.13 | 21.40 | 10.61% | 40.61% | 19.24% |
Compare IMVT vs Peers
Immunovant, Inc. (IMVT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMVT Income Statement
Immunovant, Inc. (IMVT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 21K | 0 | 0 | 0 | 0 | 0 | 206K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -21K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -206K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | 100% | - | - | - | - | - |
| Operating Expenses | 136.74M | 448 | 59.66M | 108.12M | 156.03M | 208.28M | 270.21M | 438.15M | 487.17M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.48M | 448 | 11.73M | 39.51M | 54.23M | 48.02M | 57.28M | 77.23M | 79.15M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 135.26M | 25.73M | 47.93M | 68.6M | 101.81M | 160.26M | 212.93M | 360.92M | 408.02M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -136.74M▲ 0% | -450▲ 100.0% | -59.68M▼ 13261677.8% | -108.12M▼ 81.2% | -156.03M▼ 44.3% | -208.28M▼ 33.5% | -270.21M▼ 29.7% | -438.15M▼ 62.2% | -487.17M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 100% | -13261677.78% | -81.17% | -44.32% | -33.48% | -29.74% | -62.15% | - |
| EBITDA | 0 | 9.55K | -59.66M | -108.05M | -155.91M | -208.08M | -269.98M | -437.77M | -486.75M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | -624780.63% | -81.12% | -44.29% | -33.47% | -29.75% | -62.15% | -20.22% |
| D&A (Non-Cash Add-back) | 136.74M | 10K | 21K | 65K | 126K | 193K | 231K | 377K | 422K |
| EBIT | -136.74M | -448 | -65.67M | -108.12M | -156.03M | -208.28M | -270.21M | -438.15M | -481.89M |
| Net Interest Income | 0 | 0 | -624.38K | 0 | 0 | -4.9M | 24.95M | 24.73M | 24.16M |
| Interest Income | 0 | 0 | 625 | 0 | - | 7.58M | 24.95M | 24.73M | 24.16M |
| Interest Expense | 0 | 0 | 625K | 0 | - | 12.48M | 0 | 0 | 0 |
| Other Income/Expense | 116 | 0 | -6.61M | 328K | -781K | -2.67M | 11.44M | 25.2M | 26.62M |
| Pretax Income | -136.74M▲ 0% | -448▲ 100.0% | -66.29M▼ 14796998.2% | -107.79M▼ 62.6% | -156.81M▼ 45.5% | -210.95M▼ 34.5% | -258.77M▼ 22.7% | -412.95M▼ 59.6% | -460.56M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 97K | -358K | -84K | 9K | 567K | 891K | 3.64M |
| Effective Tax Rate % | 0% | 0% | -0.15% | 0.33% | 0.05% | -0% | -0.22% | -0.22% | -0.79% |
| Net Income | -136.74M▲ 0% | -448▲ 100.0% | -66.39M▼ 14818650.0% | -107.43M▼ 61.8% | -156.73M▼ 45.9% | -210.96M▼ 34.6% | -259.34M▼ 22.9% | -413.84M▼ 59.6% | -464.2M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | 100% | -14818650% | -61.82% | -45.89% | -34.6% | -22.93% | -59.58% | -21.29% |
| Net Income (Continuing) | -136.74M | -448 | -66.39M | -107.43M | -156.73M | -210.96M | -259.34M | -413.84M | -464.2M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -13.67▲ 0% | 0.00▲ 100.0% | -1.54▲ 0% | -1.22▲ 20.8% | -1.43▼ 17.2% | -1.71▼ 19.6% | -1.88▼ 9.9% | -2.73▼ 45.2% | -2.56▲ 0% |
| EPS Growth % | - | 100% | - | 20.78% | -17.21% | -19.58% | -9.94% | -45.21% | -2.67% |
| EPS (Basic) | -13.68 | 0.00 | -1.54 | -1.22 | -1.43 | -1.71 | -1.88 | -2.73 | - |
| Diluted Shares Outstanding | 10M | 14.38M | 43.2M | 87.76M | 109.68M | 123.08M | 138.1M | 151.57M | 181.51M |
| Basic Shares Outstanding | 10M | 14.38M | 43.2M | 87.76M | 109.68M | 123.08M | 138.1M | 151.57M | 181.51M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IMVT Balance Sheet
Immunovant, Inc. (IMVT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 113.17K | 325K | 109.08M | 409.01M | 512.93M | 404.33M | 665.77M | 767.66M | 1.04B |
| Cash & Short-Term Investments | 0 | 325K | 100.57M | 400.15M | 493.82M | 376.53M | 635.37M | 713.97M | 994.52M |
| Cash Only | 0 | 325K | 100.57M | 400.15M | 493.82M | 376.53M | 635.37M | 713.97M | 994.52M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 3.04M | 1.14M | 12.86M | 885K | 5.5M | 2.51M | 1.64M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 24.9M | 51.18M | 46.77M |
| Total Non-Current Assets | 0 | 80K | 311K | 3.48M | 2.63M | 1.5M | 942K | 8.56M | 9.45M |
| Property, Plant & Equipment | 0 | 0 | 65K | 3.48M | 2.63M | 1.5M | 595K | 942K | 531K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 79.95K | 246K | 0 | 0 | 0 | 0 | 7.62M | 34.26M |
| Total Assets | 113.17K▲ 0% | 405K▲ 257.9% | 109.39M▲ 26909.1% | 412.49M▲ 277.1% | 515.56M▲ 25.0% | 405.84M▼ 21.3% | 666.71M▲ 64.3% | 776.22M▲ 16.4% | 1.05B▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 257.87% | 26909.14% | 277.09% | 24.99% | -21.28% | 64.28% | 16.43% | 191.65% |
| Total Current Liabilities | 1.61M | 380.45K | 15.32M | 18.77M | 44.52M | 43.3M | 48.61M | 68.78M | 66.26M |
| Accounts Payable | 1.14M | 0 | 1.19M | 2.43M | 18.63M | 1.35M | 7.16M | 17.66M | 8.62M |
| Days Payables Outstanding | - | - | 20.68K | - | - | - | - | - | 18.18K |
| Short-Term Debt | 0 | 300K | 3.19M | 0 | 0 | 0 | 138K | 0 | 0 |
| Deferred Revenue (Current) | 0 | -206 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | -206 | 10.94M | 3.14M | 171K | 350K | 26.57M | 15.62M | 57.64M |
| Current Ratio | 0.07x | 0.85x | 7.12x | 21.79x | 11.52x | 9.34x | 13.70x | 11.16x | 11.16x |
| Quick Ratio | 0.07x | 0.85x | 7.12x | 21.79x | 11.52x | 9.34x | 13.70x | 11.16x | 11.16x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 300K | 0 | 2.24M | 1.22M | 47K | 347K | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 2.24M | 1.22M | 47K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 347K | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.61M | 380.45K | 15.32M | 21.01M | 45.74M | 43.34M | 48.95M | 68.78M | 66.26M |
| Total Debt | 0 | 300K | 3.19M | 3.42M | 2.36M | 1.22M | 138K | 98K | 0 |
| Net Debt | 0 | -25K | -97.38M | -396.73M | -491.45M | -375.31M | -635.23M | -713.87M | -994.52M |
| Debt / Equity | - | 12.22x | 0.03x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt / EBITDA | - | 31.41x | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | -2.62x | - | - | - | - | - | - | 2.04x |
| Interest Coverage | - | - | -95.48x | - | - | -16.69x | - | - | - |
| Total Equity | -1.5M▲ 0% | 24.55K▲ 101.6% | 94.07M▲ 383041.9% | 391.48M▲ 316.2% | 469.82M▲ 20.0% | 362.49M▼ 22.8% | 617.76M▲ 70.4% | 707.45M▲ 14.5% | 986.13M▲ 0% |
| Equity Growth % | - | 101.64% | 383041.9% | 316.16% | 20.01% | -22.84% | 70.42% | 14.52% | 221.64% |
| Book Value per Share | -0.15 | 0.00 | 2.18 | 4.46 | 4.28 | 2.95 | 4.47 | 4.67 | 5.43 |
| Total Shareholders' Equity | -1.5M | 24.55K | 94.07M | 391.48M | 469.82M | 362.49M | 617.76M | 707.45M | 986.13M |
| Common Stock | 0 | 288 | 5K | 10K | 12K | 13K | 14K | 16K | 20K |
| Retained Earnings | 0 | -448 | -91.23M | -198.66M | -355.39M | -566.35M | -825.68M | -1.24B | -1.6B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.5M | 343K | -16K | -298K | 404K | 852K | 1.91M | 1.46M | 1.2M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMVT Cash Flow Statement
Immunovant, Inc. (IMVT) cash flow — operating, investing & free cash flow history
| Line item | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -128.3M | -28.55M | -53.36M | -83.33M | -106.11M | -188.19M | -214.23M | -375.87M | -375.87M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | 77.75% | -86.91% | -56.17% | -27.34% | -77.35% | -13.83% | -75.46% | -147.02% |
| Net Income | -136.74M | -28.6M | -66.39M | -107.43M | -156.73M | -210.96M | -259.34M | -413.84M | -464.2M |
| Depreciation & Amortization | 0 | 10K | 21K | 998K | 126K | 193K | 231K | 377K | 422K |
| Stock-Based Compensation | 1.81M | 1.31M | 6.96M | 0 | 34.24M | 32.3M | 41.12M | 49.49M | 56.27M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.19M | -792K | 1.24M | 18.54M | 1.11M | 1.13M | 1.13M | 133K | 95K |
| Working Capital Changes | 1.44M | -474K | 4.81M | 4.57M | 15.14M | -10.85M | 2.63M | -12.03M | -15.48M |
| Change in Receivables | 0 | 0 | -83K | 2.5M | -11.72M | 12.22M | -4.56M | 2.97M | 247K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 967K | 1.25M | 16.25M | -17.12M | 5.78M | 10.68M | -11.21M |
| Cash from Investing | 0 | -52K | -31K | -210K | -254K | -197K | -360K | -759K | -201K |
| Capital Expenditures | 0 | -52K | -31K | -210K | -254K | -197K | -360K | -759K | -201K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 128.3M | 35.58M | 146.97M | 383.11M | 200.13M | 70.89M | 472.43M | 454.49M | 1.04B |
| Debt Issued (Net) | 0 | 0 | 37.91M | -3.19M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 1000K | 0 | 1000K | 1000K | 1000K | 4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 128.3M | 35.58M | 109.07M | 0 | 200.13M | 385K | -318K | 4.49M | 612K |
| Net Change in Cash | 0▲ 0% | 6.99M▲ 0% | 93.59M▲ 1239.8% | 299.57M▲ 220.1% | 93.67M▼ 68.7% | -117.28M▼ 225.2% | 258.83M▲ 320.7% | 78.61M▼ 69.6% | 619.84M▲ 0% |
| Free Cash Flow | -128.3M▲ 0% | -28.6M▲ 77.7% | -53.39M▼ 86.7% | -83.54M▼ 56.5% | -106.37M▼ 27.3% | -188.39M▼ 77.1% | -214.59M▼ 13.9% | -376.63M▼ 75.5% | -423.09M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | 77.71% | -86.68% | -56.47% | -27.33% | -77.11% | -13.91% | -75.52% | -29.92% |
| FCF per Share | -12.83 | -1.99 | -1.24 | -0.95 | -0.97 | -1.53 | -1.55 | -2.48 | -2.48 |
| FCF Conversion (FCF/Net Income) | 0.94x | 63720.98x | 0.80x | 0.78x | 0.68x | 0.89x | 0.83x | 0.91x | 0.91x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 61K | 0 | 0 | 0 | 509K | 1.2M | 901K |
IMVT Key Ratios
Immunovant, Inc. (IMVT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -1.82% | -141.11% | -44.25% | -36.39% | -50.69% | -52.91% | -62.46% | -47.07% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | 19876.5% |
| Debt / Equity | 12.22x | 0.03x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x |
| Interest Coverage | - | -95.48x | - | - | -16.69x | - | - | - |
| FCF Conversion | 63720.98x | 0.80x | 0.78x | 0.68x | 0.89x | 0.83x | 0.91x | 0.91x |
IMVT SEC Filings & Documents
Immunovant, Inc. (IMVT) SEC filings — annual & quarterly reports (10-K, 10-Q)
IMVT Frequently Asked Questions
Immunovant, Inc. (IMVT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immunovant, Inc. (IMVT) grew revenue by 0.0% over the past year. Growth has been modest.
Immunovant, Inc. (IMVT) reported a net loss of $464.2M for fiscal year 2025.
Dividend & Returns
Immunovant, Inc. (IMVT) has a return on equity (ROE) of -62.5%. Negative ROE indicates the company is unprofitable.
Immunovant, Inc. (IMVT) had negative free cash flow of $423.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More IMVT
Immunovant, Inc. (IMVT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates